A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trial

Gerardo Rosati, Roberto Labianca, Luigi Cavanna et al.|Gastric Cancer|2022

Cited by 4